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Sex Med 2Introduction: Hyaluronic acid has been shown to be efﬁcacious in decreasing scar formation, inﬂammation, and
oxidative stress.
Aim: To assess the efﬁcacy of intralesional injection of hyaluronic acid in patients affected by Peyronie’s disease.
Methods: In this prospective, single-arm, self-controlled, interventional, multicenter pilot study, 65 patients
underwent a 10-week cycle of weekly intraplaque injections with hyaluronic acid (0.8% highly puriﬁed sodium
salt hyaluronic acid 16 mg/2 mL; Sinovial, IBSA, Lodi, Italy). Patients were re-evaluated 2 months after the end
of therapy.
Main Outcome Measures: Plaque size (millimeters), penile curvature (degrees), International Index of Erectile
Function (IIEF-5) score, visual analog scale (VAS) score for sexual satisfaction, and Patient’s Global Impressions
of Improvement (PGI-I) score.
Results: Median age was 57 years (range ¼ 23e70). At baseline, mean plaque size was 10 mm (range ¼ 3e30
mm), mean penile curvature was 30 (range ¼ 0e50), and mean IIEF-5 score was 20 (range ¼ 0e25), with
slight to moderate erectile dysfunction (IIEF score < 21) in 36 of 65 patients (55%). A median VAS score of
6 (range ¼ 2e10) was found. Mean follow-up was 12 months (range ¼ 6e24 months). Statistically signiﬁcant
post-treatment improvements were detected for plaque size (before treatment ¼ 10 mm [3e30 mm], after
treatment ¼ 8 mm [1e30 mm], P < .0001), penile curvature (before treatment ¼ 30 [0e50], after
treatment ¼ 20 [0e40], P < .0001), IIEF-5 score (before treatment ¼ 20 [11e25], after treatment ¼ 21
[15e25], P < .0001), and VAS score (before treatment ¼ 6 [2e10], after treatment 8 [2e10], P < .0001). After
treatment, the rate of patients with an IIEF score lower than 21 decreased from 55% (36 patients) to 40% (25
patients). Overall improvement on the PGI-I questionnaire was 69%.
Conclusion: Intralesional treatment with hyaluronic acid can improve plaque size, penile curvature, and overall
sexual satisfaction and seems preferably indicated in the early (active) phase of the disease. Furthermore, it is easy
to perform and well tolerated.
Sex Med 2016;4:e85ee90. Copyright  2016, The Authors. Published by Elsevier Inc. on behalf of the International
Society for Sexual Medicine. This is an open access article under the CC BY-NC-ND license (http://creativecommons.
org/licenses/by-nc-nd/4.0/).
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Peyronie’s disease (PD) is an acquired, localized ﬁbrotic dis-
order characterized by the deposition of collagen and ﬁbrin in the
form of plaque on the tunica albuginea of the penis. Its patho-
physiology is unknown and frequently results in penile defor-
mity, penile pain, and erectile dysfunction,1 leading to a
signiﬁcant negative impact on patient quality of life, with asso-
ciated rates of signiﬁcant depression up to 48%.2 Recent prev-
alence estimates vary from 3.2% to 8.9%.3,4
The etiology of PD is largely unknown. According to current
popular theories, a single traumatic event or repeated micro-
traumas during sexual activity can lead to a low-level autoim-
mune response arising from a prolonged and complex
inﬂammatory reaction of the tunica albuginea ﬁbers,5 which
leads to plaque formation.6e9
From a historical point of view, it is worth highlighting that
the ﬁrst descriptions of a penile condition that could refer to PD
probably date to the 13th century, and the ﬁrst accurate
description of PD was reported by the Italian anatomist Gabriele
Falloppio in the 16th century. In 1743, Francois Gigot de la
Peyronie’s wrote a landmark article on PD, and his name was
associated with the disease. Despite this long history, there are no
medical or surgical therapies10 and there is a paucity of knowl-
edge on the natural history of PD, although deformity stabili-
zation and improvements in speciﬁc subsets of men with
untreated PD have recently been reported.11
The European Association of Urology and the American As-
sociation of Urology have released clinical practice guidelines for
the diagnosis, evaluation, treatment, and follow-up of patients
with PD.12,13 Conservative treatment of PD is focused primarily
on patients in the early (acute inﬂammatory) stage, and surgical
remediation is used to correct curvature, allow for satisfactory
intercourse, and is reserved for patients who have stable disease
for at least 12 months.12
Several options have been suggested for non-operative PD
treatment, including oral pharmacotherapy, intralesional injection
therapy, and other topical treatments. Of these, injection of
pharmacologically active agents directly into penile plaques rep-
resents the most valid treatment option, because current evidence
discourages the use of oral and topical agents. In particular, current
American Association of Urology clinical practice guidelines
suggest intralesional administration of Clostridium histolyticum
collagenase (CHC) in combination with modeling or intralesional
interferon alfa-2b or verapamil.14However, these compounds have
been found to produce the potential occurrence of mild to severe
adverse events, including penile ecchymosis, swelling, pain, and
corporal rupture with collagenase; sinusitis, ﬂulike symptoms, and
minor penile swelling with interferon alfa-2b; and penile bruising,
dizziness, nausea, and pain at the injection site with verapamil.14 In
addition, therapy with collagenase is limited by the high cost of the
compound. Based on currently available scientiﬁc evidence, the
intralesional agent presenting the optimal beneﬁt-risk ratio is farfrom determined, and further research of novel intralesional agents
is strongly needed.
Hyaluronic acid has been shown to be efﬁcacious in decreasing
scar formation and blocking the effects of substances that generate
inﬂammation and oxidative stress. For this reason, it is used
widely in numerous medical applications, including cosmetic
surgery (for treatment of wrinkles and scar) and orthopedics
(intra-articular therapy for osteoarthritis) because of its consoli-
dated therapeutic efﬁcacy and treatment-cycle feasibility.15,16
The present study investigated whether intralesional use of
hyaluronic acid could provide a positive effect on the patho-
genesis of PD by its interference with inﬂammatory and
pro-ﬁbrotic processes. Therefore, the aim of this prospective,
single-arm, self-controlled, interventional, multicenter pilot
study was to assess the efﬁcacy of intralesional injections of hy-
aluronic acid to decrease plaque size, decrease penile curvature,
and increase sexual satisfaction in patients affected by PD.METHODS
This is a single-arm, self-controlled, interventional study.
Patients were enrolled from 10 Italian andrology centers and
pretreatment clinical evaluations were carried out by urologists
experienced with PD management.
Sexually active men older than 18 years affected by PD were
eligible for this study. Study criteria included (i) a palpable nodule
or plaque in the tunica of the penis and (ii) pain in theﬂaccid state or
during painful erections. Exclusion criteria were (i) calciﬁed plaques
or hourglass deformity as deﬁned at duplex Doppler ultrasonog-
raphy, (ii) previous PD therapy with oral agents or intralesional
injections, and (iii) severe concomitant erectile dysfunction (In-
ternational Index of Erectile Function [IIEF-5] score < 7).
After the preliminary evaluation for eligibility, including
medical and sexual histories, physical examination, and self-
administration of IIEF-5 questionnaires, enrolled patients were
invited to undergo a 10-week cycle of weekly intraplaque
injections with hyaluronic acid (0.8% highly puriﬁed sodium salt
hyaluronic acid 16 mg/2 mL,; Sinovial, IBSA, Lodi, Italy).
All patients provided written informed consent and the study
was approved by the institutional review board (ethics committee
of Perugia University, Perugia, Italy).Pretreatment Workup
All patients underwent Duplex Doppler ultrasonography in
the basal condition and after the induction of penile erection
with the assistance of an intracavernous injection of a tri-mix
(papaverine 30 mg/mL, phentolamine 1 mg/mL, alprostadil
10 mg/mL). Repeat dosing was administered to a maximum of
three doses until full erectile rigidity was achieved. All procedures
were performed by the same experienced operator at each center.
Plaque position and size (the longest diameter was considered
when evaluating the results) were carefully assessed. PenileSex Med 2016;4:e85ee90
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rigidity. Patients were stratiﬁed in six categories according to penile
curvature: 0 to 10, 10 to 20, 20 to 30, 30 to 40, 40 to 50,
and greater than 50. Self-assessment of sexual satisfaction was
measured using a visual analog scale (VAS) from 0 to 10, where
0 represented “not satisﬁed” and 10 represented “satisﬁed.”Follow-Up
Two months after the end of therapy, penile curvature and
plaque size were re-evaluated with Duplex Doppler ultrasonogra-
phy as described earlier and the results were compared with the
pretreatment values. To assess sexual satisfaction, patients repeated
the IIEF-5 questionnaire andVAS for sexual satisfaction. They also
ﬁlled out the Patient’sGlobal Impressions of Improvement (PGI-I)
questionnaire, which is a one-item questionnaire designed to assess
the patient’s impression of changes in his condition.16 The PGI-I
asks the patient to best describe his current condition compared
with before treatment. Answers are given on a seven-point scale
(1 ¼ a lot better, 2 ¼ much better, 3 ¼ a little better, 4 ¼ no
change, 5 ¼ a little worse, 6 ¼ much worse, 7 ¼ a lot worse).Statistical Analysis
The Shapiro-Wilk test was used to assess the normal distri-
bution of variables. The Wilcoxon signed rank test was used to
compare paired data and Spearman r was used to examine cor-
relations. Statistical analyses were performed using IBM-SPSS
22.0 (IBM Corp, Armonk, NY, USA). A two-sided P value
less than 0.05 was considered signiﬁcant.Table 2. Clinical results after 10 intraplaque injections with
hyaluronic acid*RESULTS
From December 2012 through December 2014, 118 patients
with PD were screened. Of these, 65 patients met the inclusion
criteria and received 10 weekly treatments with hyaluronic acid.
All patients completed the treatment cycle and attended the ﬁrst
follow-up visit (2 months after the end of therapy).
Table 1 presents the demographics and clinical data of the study
group. Median age was 57 years (range ¼ 23e70 years). All pa-
tients described the onset of PD as pain, tension, or “tingling”
during erection, curvature, and/or erectile dysfunction. Mean
elapsed time from disease onset (symptoms and/or curvature) to
diagnosis was 4.3months (range¼ 1e18months). All patients had
at least one palpable plaque on the shaft at physical examination. At
baseline, mean plaque size was 10 mm (range¼ 3e30mm), meanTable 1. Demographics and baseline clinical data
Baseline parameter Median Range SD
Age (y) 57 23e70 10.88
Plaque dimensions (mm) 10 3e30 6.76
Penile curvature () 30 0e50 1.13
IIEF-5 score 20 11e25 4.72
VAS score 6 2e10 2.08
IIEF ¼ International Index of Erectile Function; VAS ¼ visual analog scale.
Sex Med 2016;4:e85ee90curvature was 30 (range ¼ 0e50), and mean baseline IIEF-5
score was 20 (range ¼ 0e25), with slight to moderate erectile
dysfunction (IIEF score< 21) present in 36 of 65 patients (55%).
A median VAS score of 6 (range ¼ 2e10) was detected. Mean
follow-up was 12 months (range ¼ 6e24 months).
Table 2 lists the results after treatment for plaque size, penile
curvature, and IIEF-5 and VAS scores. Statistically signiﬁcant
post-treatment improvements were detected for plaque size
(before treatment ¼ 10 mm [3e30 mm], after treatment ¼ 8
mm [1e30 mm], P < .0001), curvature (before treatment¼ 30
[0e50], after treatment ¼ 20 [0e40], P < .0001), IIEF-5
score (before treatment ¼ 20 [11e25], after treatment ¼ 21
[15e25], P < .0001), and VAS score (before treatment ¼ 6
[2e10], after treatment ¼ 8 [2e10], P < .0001). After treat-
ment, the rate of patients with an IIEF score lower than 21
decreased from 55% (36 patients) to 40% (25 patients).
Figure 1 presents additional details of the treatment effect on
plaque size. At the end of treatment, plaque size was smaller in
37 patients (57%), remained unchanged (stable) in 24 (37%),
and was larger in 4 (6%).
Overall improvement on the PGI-I questionnaire was 69%.
Eight patients declared they felt “a lot better,” 16 felt “much
better,” 21 felt “a little better,” 14 perceived “no change,” and 6
(9%) felt worse after treatment.
No injection-site ecchymosis or hematomas and no patient-
reported pain during injection, local or systemic drug reactions,
including adverse side effects or sensory changes at the tip of the
penis, were noted.DISCUSSION
This prospective, single-arm, self-controlled, interventional,
multicenter pilot study investigated the efﬁcacy of hyaluronic
acid as intralesional treatment for patients with PD and showed
encouraging preliminary results for improvement in plaque size,
penile curvature, and overall sexual satisfaction.
Hyaluronic acid is a glycosaminoglycan found in the extra-
cellular matrix. At physiologic pH, the hyaluronate molecule is
highly polarized and, hence, highly soluble in water. The marked
uptake of water molecules by hyaluronic acid maintains hydra-
tion, turgor, plasticity, and viscosity in the amorphousParameter
Before
treatment
After
treatment P value
Plaque size (mm) 10 (3e30) 8 (1e30) <.0001
Penile curvature () 30 (0e50) 20 (0e40) <.0001
IIEF-5 (score) 20 (11e25) 21 (15e25) <.0001
Sexual satisfaction
(VAS score)
6 (2e10) 8 (2e10) <.0001
IIEF ¼ International Index of Erectile Function; VAS ¼ visual analog scale.
*Data are expressed as median (range).
Figure 1. Plaque size before and after treatment course.
e88 Zucchi et alconnective tissue matrix. It also acts as an antishock molecule and
a lubricant as, for example, in synovial ﬂuid, thus protecting cells
from physical stress.15,16 It is most commonly used to treat
osteoarthritis of the knee, where oxidative stress plays a major
role in cartilage degeneration and disease onset. Oxygen-free
radicals, such as hydrogen peroxide (H2O2), hypochlorite ions,
(OCl), the hydroxyl radical ($OH), and superoxide anions
(O2
), are involved in intracellular signal transduction and
degenerative cellular processes.15,16 High levels of oxygen-free
radicals cause chondrocyte apoptosis and cartilage degeneration,
thus contributing to the pathogenesis of osteoarthritis.17,18 A
general consensus is that, in osteoarthritis, hyaluronic acid de-
creases oxygen-free radicals in the synovial ﬂuid, inhibits
apoptosis, promotes cell survival,19 and decreases concentrations
of inﬂammatory proteins.20 As a result, hyaluronic acid acts as an
antioxidant and as an anti-inﬂammatory agent.
The same type of cells involved in osteoarthritis play a funda-
mental role in the pathophysiology of PD. In the early stages of PD,
oxidative stress induces overexpression of ﬁbrogenic cytokines and
increases collagen synthesis. Tumor growth factor-b1 increases levels
of oxygen free radicals,21 and these are the main mediators of
collagen synthesis because they decrease local collagenase activity
and stimulate overproduction of extracellular matrix proteins. The
inﬂammation associated with PD involves overexpression of
inducible nitric oxide synthase and peroxynitrite production in the
corpus cavernosum and ﬁbroblasts. This results when nitric oxide
levels increase and oxygen and nitrogen radicals react with super-
oxide dismutase to produce highly toxic and pro-ﬁbroticperoxynitrite (ONOO). Adverse effects ofONOO in the corpus
cavernosum include lipid peroxidation, DNA fragmentation, pro-
tein damage, and nitration that cause cellular damage and lead to
collagen accumulation and eventually organ dysfunction.22,23
PD has been treated with some success by intralesional injection
of different drugs, particularly when patients are in the early, painful
progressive stages, do not have calciﬁed plaques, and have a short
case history. Currently, corticosteroids and verapamil are those
most commonly used.12e14 However, only one single-blinded,
placebo-controlled study has been performed using corticoste-
roids.24 In a recent non-randomized study, Bennett et al25 treated
94 patients with six intralesional verapamil injections administered
on alternating weeks. Penile pain was alleviated in all patients and
18% showed decreased curvature. A randomized, single-blinded,
placebo-controlled trial comparing intralesional verapamil with
saline showed no signiﬁcant difference or improvement in penile
curvature, pain, plaque features, or sexual function,26 whereas
administration of the calcium channel blocker nicardipine provided
signiﬁcant improvements in IIEF-5 score and plaque size.27
A single-blinded, placebo-controlled study investigated the
efﬁcacy of interferon in treating plaques in 103 patients with PD
who received intralesional inﬁltrations of interferon alfa-2b for 12
weeks. Compared with placebo, interferon inﬁltration signiﬁcantly
decreased mean penile curvature (27% vs 8.9%), mean plaque size
(54.6% vs 19.8%), and mean plaque density (33.3% vs 11.1%).28
In patients presenting with stable PD, CHC was proposed as
effective in alleviating symptoms. In a double-blinded, placebo-
controlled study of 49 patients, CHC decreased plaque number
and size and penile curvature in 36% of patients compared with
4% in those who received placebo.29 It is worth noting that CHC
is indicated in patients with stable plaque, whereas hyaluronic acid
should be considered an alternative option in early-stage PD; thus,
the two compounds should not be directly compared.
Table 3 presents a summary comparison of major series
investigating intralesional therapies for every stage of PD.
Currently, most drugs used for intraplaque injection in PD are
“off-label,” with a risk of systemic (verapamil, steroids) and local
(collagenase) side effects. In contrast, hyaluronic acid showed a
low risk of local or systemic adverse effects.
In the present study, hyaluronic acid was used because of its
anti-inﬂammatory and antioxidant effects, which led to early
resolution of plaque-related symptoms and its antiﬁbrotic effects,
which limited plaque growth. A decrease in plaque size was
found in more than half the patients (57%), whereas an increase
was observed in only 6%.
Although the plaque size measurement might be inﬂuenced by
inter-operator variability, we interpreted the resulting decrease in
plaque size as directly relevant to treatment and a sign of limited
plaque evolution attributable to treatment efﬁcacy.
Statistical analysis showed that curvature was decreased in 37%
of patients and signiﬁcant improvements were found in the IIEF-5Sex Med 2016;4:e85ee90
Table 3. Comparison among major series investigating intralesional therapies for Peyronie’s disease
Levine et al,14 2002 Hellstrom et al,28 2006 Bennett et al,25 2007 Present study
Patients, n 156 117 94 65
Drug Verapamil Interferon alfa2b Verapamil Hyaluronic acid
Dose 10 mg every 2 wk 2  106 U biweekly 10 mg every 2 wk 8 mg/wk
Study design Prospective,
non-randomized,
single-arm study
Single-blinded, multicenter,
placebo-controlled,
parallel-group study
Prospective,
non-randomized,
single-arm study
Prospective,
non-randomized,
single-arm,
multicenter,
pilot study
Injections, n 12 6 6 10
Decrease in penile curvature, % 60 27 18 37
Increased sexual satisfaction, % 71 Not available Monopoli Monopoli
Decrease in plaque size, % Not available 54.6 Not available 57
Hyaluronic Acid in Peyronie’s Disease e89and VAS sexual satisfaction scores compared with pretreatment
data. Although the net numeric increase of the IIEF-5 score was
minimal, it is worth noting that, after the treatment course, most
patients presented with restored erectile function (IIEF-5 score
>21) and signiﬁcant overall subjective improvement in sexual
function. Furthermore, the reported improvement in plaque size
and penile curvature, even if statistically meaningful, is numeri-
cally minimal. Regardless of statistical power, these results are
clinically relevant because they trigger a positive behavior in the
patient affected by PD, as demonstrated by the net increase in
sexual satisfaction. Unfortunately, the lack of comparison with a
placebo arm limits the relevancy of these data.
Hyaluronic acid was well tolerated in all patients in terms of
local and systemic side effects, which can be considered a true
advantage compared with other available intralesional drugs.
Another point is that in our patient cohort the mean elapsed time
from disease onset (symptoms and/or curvature) to diagnosis was
4.3 months, suggesting early-stage disease in most cases. Based on
the mechanisms of action of hyaluronic acid, we speculate that its
optimal efﬁcacy rate can be achieved in this speciﬁc subset of
patients with PD. Nevertheless, there are several limitations to the
present study that must be considered when interpreting the re-
sults. First, the study design was not randomized and not
controlled with placebo. Second, the study sample was limited and
was recruited from 10 different centers with a limited number of
cases in some centers; a sub-analysis of results according to single-
center experience was not performed. We emphasize that if the
multicenter enrollment is considered a bias for patients’ baseline
characteristics, then it should be considered representative of a
“real-life” setting, thus supporting the strength of the study.
Third, improvement in sexual function satisfaction was assessed
using a VAS rather than other available validated tools.
Further prospective, randomized, placebo-controlled studies
with larger patient cohorts stratiﬁed by disease stage are sorely
needed to establish the real impact of intralesional hyaluronic
acid as a therapeutic option for early-stage PD, other than con-
ﬁrming the high treatment tolerability.Sex Med 2016;4:e85ee90CONCLUSIONS
This prospective, multicenter, pilot study assessing the efﬁcacy
of hyaluronic acid as intralesional treatment for patients with PD
showed encouraging preliminary results for improvement of
plaque size, penile curvature, and overall sexual satisfaction. This
therapeutic approach seems to be preferably indicated in the early
(active) phase of the disease. Intralesional treatment with hyal-
uronic acid is easy to perform and well tolerated, with null risk of
local or systemic side effects.
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